Organogenesis Holdings (ORGO) Cash & Equivalents (2016 - 2025)
Organogenesis Holdings (ORGO) has 9 years of Cash & Equivalents data on record, last reported at $93.7 million in Q4 2025.
- For Q4 2025, Cash & Equivalents fell 30.9% year-over-year to $93.7 million; the TTM value through Dec 2025 reached $93.7 million, down 30.9%, while the annual FY2025 figure was $93.7 million, 30.9% down from the prior year.
- Cash & Equivalents reached $93.7 million in Q4 2025 per ORGO's latest filing, up from $63.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $135.6 million in Q4 2024 and bottomed at $63.7 million in Q3 2025.
- Average Cash & Equivalents over 5 years is $98.4 million, with a median of $98.2 million recorded in 2023.
- Peak YoY movement for Cash & Equivalents: soared 35.0% in 2021, then tumbled 32.43% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $113.9 million in 2021, then decreased by 10.05% to $102.5 million in 2022, then rose by 1.33% to $103.8 million in 2023, then soared by 30.56% to $135.6 million in 2024, then crashed by 30.9% to $93.7 million in 2025.
- Per Business Quant database, its latest 3 readings for Cash & Equivalents were $93.7 million in Q4 2025, $63.7 million in Q3 2025, and $73.1 million in Q2 2025.